Company news
BioVersys AG news in 2025
BioVersys AG's news releases, calls and decks from 2025, newest first.
BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
December 11, 2025
BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network
November 10, 2025
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
September 10, 2025
BioVersys Receives EMA Orphan Designation for the Combination of Alpibectir and Ethionamide for the Treatment of Tuberculosis
August 27, 2025
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
July 2, 2025
BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024
March 26, 2025